Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.

Pouwels XGLV, Geurts SME, Ramaekers BLT, Erdkamp F, Vriens BEPJ, Aaldering KNA, van de Wouw AJ, Dercksen MW, Smilde TJ, Peters NAJB, Riel JMV, Pepels MJ, Heijnen-Mommers J, Joore MA, Tjan-Heijnen VCG, de Boer M.

Acta Oncol. 2019 Oct 4:1-8. doi: 10.1080/0284186X.2019.1670356. [Epub ahead of print]

PMID:
31583931
2.

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Pijl H, Charehbili A, van de Ven S, Smit VTHBM, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJC, Kessels LW, Dercksen MW, Pepels MJAE, van Laarhoven HWM, Vriens BEPJ, Putter H, Fiocco M, Liefers GJ, van der Hoeven JJM, Nortier JWR, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2019 Aug 28;21(1):97. doi: 10.1186/s13058-019-1180-6.

3.

A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.

Knapen LM, Geurts SME, Ibragimova KIE, Croes S, Vriens BEPJ, van den Berkmortel FWPJ, Dercksen MW, van de Wouw AJ, Pepels MJAE, de Fallois AOJ, Lobbezoo DJA, de Boer M, Tjan-Heijnen VCG.

Breast. 2019 Apr;44:46-51. doi: 10.1016/j.breast.2019.01.001. Epub 2019 Jan 4.

4.

[Infection or metastases? The amoebic abscess].

Heil TC, Dercksen MW, Blank SN.

Ned Tijdschr Geneeskd. 2018 Jul 20;162. pii: D2580. Dutch.

PMID:
30182627
5.

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium.

Seferina SC, Ramaekers BLT, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJW, van de Wouw AJ, Voogd AC, Tjan Heijnen VCG, Joore MA.

Oncotarget. 2017 Apr 9;8(45):79223-79233. doi: 10.18632/oncotarget.16985. eCollection 2017 Oct 3.

6.

Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.

Aarts MJ, Vriens BE, de Boer M, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Tol J, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, van der Rijt CCD, Smilde TJ, van der Velden AW, Peer N, Tjan-Heijnen VCG.

Oncology. 2017;93(5):323-328. doi: 10.1159/000479067. Epub 2017 Aug 22.

PMID:
28848182
7.

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.

van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, de Boer M, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FPJ, van Riel JMG, Peters NAJB, Tjan-Heijnen VCG, Joore MA.

Eur J Cancer. 2017 Jul;79:238-246. doi: 10.1016/j.ejca.2017.01.027. Epub 2017 Feb 27.

PMID:
28245951
8.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
9.

The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.

Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen MW, van den Berkmortel F, Smilde T, van de Wouw A, van Kampen R, van Riel J, Peters N, Peer P, Tjan-Heijnen VC.

Oncotarget. 2016 May 17;7(20):29412-9. doi: 10.18632/oncotarget.8838.

10.

In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC.

Ann Oncol. 2016 Feb;27(2):256-62. doi: 10.1093/annonc/mdv544. Epub 2015 Nov 16.

PMID:
26578730
11.

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.

Seferina SC, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, de Vries B, Joore MA, Peer PG, Voogd AC, Tjan-Heijnen VC.

Oncologist. 2015 Aug;20(8):856-63. doi: 10.1634/theoncologist.2015-0006. Epub 2015 Jun 22.

12.

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC.

Br J Cancer. 2015 Apr 28;112(9):1445-51. doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16.

13.

Two patients with a neuroendocrine tumour of the small intestine and paraneoplastic myasthenia gravis.

Hermans MA, Stelten BM, Haak HR, de Herder WW, Dercksen MW.

Endocrinol Diabetes Metab Case Rep. 2014;2014:140013. doi: 10.1530/EDM-14-0013. Epub 2014 May 1.

14.

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.

Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

PMID:
24166522
15.

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.

PMID:
24104881
16.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.

Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29.

PMID:
23630211
17.

Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia.

Vleut RE, van Poppel JE, Dercksen MW, Peerbooms M, Houterman S, Breed WP.

Support Care Cancer. 2013 Jul;21(7):1807-14. doi: 10.1007/s00520-013-1723-9. Epub 2013 Jan 22.

PMID:
23338231
18.

Evaluation of Cohen's cross-section trichometer for measuring hair quantity.

Hendriks MA, Geerts PA, Dercksen MW, van den Hurk CJ, Breed WP.

Dermatol Surg. 2012 Apr;38(4):631-4. doi: 10.1111/j.1524-4725.2011.02176.x. Epub 2012 Jan 23.

PMID:
22268669
19.

[Sweet syndrome in underlying malignancy].

van Hirtum PV, Prins M, ten Oever J, Nijziel MR, Vreugdenhil G, Dercksen MW.

Ned Tijdschr Geneeskd. 2010;154:A2112. Dutch.

PMID:
21040604
20.

Response to radiation therapy in adrenocortical carcinoma.

Hermsen IG, Groenen YE, Dercksen MW, Theuws J, Haak HR.

J Endocrinol Invest. 2010 Nov;33(10):712-4. doi: 10.3275/6904. Epub 2010 Mar 10.

PMID:
20220294
21.

Complete remission of MDS RAEB following immunosuppressive treatment in a patient with Sweet's syndrome.

Ten Oever J, Kuijper PH, Kuijpers AL, Dercksen MW, Vreugdenhil G.

Neth J Med. 2009 Sep;67(8):347-50.

22.

Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis.

van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR.

Int J Cancer. 2007 May 1;120(9):1986-92.

23.

[Haemoptysis as a complication of Behçet's disease].

van den Brand JJ, van den Bosch JM, Seldenrijk CA, Dercksen MW, Ruitenberg HM, Schramel FM.

Ned Tijdschr Geneeskd. 2005 Jul 16;149(29):1631-5. Dutch.

PMID:
16078772
24.

E-selectin and very late activation antigen-4 mediate adhesion of hematopoietic progenitor cells to bone marrow endothelium.

Rood PM, Dercksen MW, Cazemier H, Kerst JM, Von dem Borne AE, Gerritsen WR, van der Schoot CE.

Ann Hematol. 2000 Sep;79(9):477-84.

PMID:
11043418
25.

The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets.

Dercksen MW, Weimar IS, Richel DJ, Breton-Gorius J, Vainchenker W, Slaper-Cortenbach CM, Pinedo HM, von dem Borne AE, Gerritsen WR, van der Schoot CE.

Blood. 1995 Nov 15;86(10):3771-82.

PMID:
7579344
26.

Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation.

Dercksen MW, Rodenhuis S, Dirkson MK, Schaasberg WP, Baars JW, van der Wall E, Slaper-Cortenbach IC, Pinedo HM, Von dem Borne AE, van der Schoot CE, et al.

J Clin Oncol. 1995 Aug;13(8):1922-32.

PMID:
7543561
27.

Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.

Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-Cortenbach IC, Schaasberg WP, Pinedo HM, von dem Borne AE, van der Schoot CE.

Blood. 1995 Jun 1;85(11):3313-9.

PMID:
7538823
28.

Hypotension induced by interleukin-3 in patients on angiotensin-converting enzyme inhibitors.

Dercksen MW, Hoekman K, Visser JJ, ten Bokkel Huinink WW, Pinedo HM, Wagstaff J.

Lancet. 1995 Feb 18;345(8947):448. No abstract available.

PMID:
7853962
29.

Further studies to ameliorate toxicity of carboplatin.

ten Bokkel Huinink WW, Dercksen MW, van Tinteren H.

Semin Oncol. 1994 Apr;21(2 Suppl 2):27-33; quiz 34, 58.

PMID:
8202718
30.

Mobilization and homing of haematopoietic progenitor cells.

van der Schoot CE, Dercksen MW.

Vox Sang. 1994;67 Suppl 3:221-6. Review. No abstract available.

PMID:
7975497
31.

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

Dercksen MW, Hoekman K, ten Bokkel Huinink WW, Rankin EM, Dubbelman R, van Tinteren H, Wagstaff J, Pinedo HM.

Br J Cancer. 1993 Nov;68(5):996-1003.

32.

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M.

J Virol. 1992 Mar;66(3):1354-60.

33.

HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M.

AIDS. 1992 Jan;6(1):49-54.

PMID:
1543566

Supplemental Content

Loading ...
Support Center